pravastatin has been researched along with Neoplasms in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 14 (51.85) | 29.6817 |
| 2010's | 9 (33.33) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Gussekloo, J; Jukema, JW; le Cessie, S; Marijt, KA; Mooijaart, SP; Rostamian, S; Trompet, S; van Buchem, MA; van Hall, T | 1 |
| Alexandre, L; Loke, YK; Thomas, JP | 1 |
| Blankenberg, S; Elliott, J; Espinoza, D; Glasziou, PP; Hague, W; Keech, AC; Nestel, PJ; Robledo, KP; Simes, J; Stewart, RA; Sullivan, DR; Tonkin, AM; White, HD; Zeller, T | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| Garnett, DJ; Greenhough, TJ | 1 |
| Ford, I; McCowan, C; Murray, H; Packard, CJ | 1 |
| Xiao, H; Yang, CS | 1 |
| Ravnskov, U | 1 |
| Hattori, Y; Iwashita, M; Kaburagi, J; Matsushita, Y; Ozawa, M; Saito, H; Sugihara, M; Yoshida, S | 1 |
| Bonovas, S; Nikolopoulos, G; Sitaras, NM | 2 |
| Banciu, M; Cabaj, M; Coimbra, M; de Smet, L; Fens, MH; Metselaar, JM; Schiffelers, RM; Storm, G | 1 |
| Chakraborty, K; Harirforoosh, S; Hsi, L; Krishnan, K; Menter, DG; Newman, RA; Ramsauer, VP; Yang, P | 1 |
| Goldstein, MR | 1 |
| Branchi, A; Fiorenza, AM; Sommariva, D | 1 |
| Stefanec, T | 1 |
| Hunt, D; Kirby, A; Liew, D; Magliano, D; Pater, H; Simes, J; Sundararajan, V; Tonkin, A | 1 |
| Ajiki, W; Awata, N; Kobayashi, T; Sato, S | 1 |
| Brophy, JM | 1 |
| Bonovas, S; Sitaras, NM | 1 |
| Archer, MC; Duncan, RE; El-Sohemy, A | 1 |
| Alsheikh-Ali, AA; Han, H; Karas, RH; Maddukuri, PV | 1 |
| Brophy, MT; Farwell, WR; Fiore, LD; Gaziano, JM; Lawler, EV; Lew, RA; Scranton, RE | 1 |
| Cobbe, SM; Ford, I; Isles, CG; Lorimer, AR; MacFarlane, PW; McKillop, JH; Packard, CJ; Shepherd, J | 1 |
| Aoyama, T; Iwata, H; Kami, M | 1 |
7 review(s) available for pravastatin and Neoplasms
| Article | Year |
|---|---|
Association of cognitive function with increased risk of cancer death and all-cause mortality: Longitudinal analysis, systematic review, and meta-analysis of prospective observational studies.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cognition; Cognitive Dysfunction; Female; Humans; Male; Neoplasms; Pravastatin; Prospective Studies | 2022 |
Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pravastatin; Progression-Free Survival; Randomized Controlled Trials as Topic; Time Factors | 2020 |
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan.
Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; Female; Humans; Japan; Male; Middle Aged; Neoplasms; Pravastatin; Risk Factors | 2010 |
Does pravastatin promote cancer in elderly patients? A meta-analysis.
Topics: Age Factors; Aged; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk | 2007 |
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.
Topics: Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver Diseases; Lovastatin; Neoplasms; Pravastatin; Rhabdomyolysis; Simvastatin | 2007 |
4 trial(s) available for pravastatin and Neoplasms
| Article | Year |
|---|---|
Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Neoplasms; Pravastatin; Proportional Hazards Models; Risk; Smoking | 2006 |
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Humans; Hypercholesterolemia; Incidence; Male; Middle Aged; Myocardial Infarction; Neoplasms; Pravastatin; Risk; Survival Analysis | 1995 |
Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group.
Topics: Adverse Drug Reaction Reporting Systems; Coronary Disease; Double-Blind Method; Enzyme Inhibitors; Follow-Up Studies; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Record Linkage; Medical Records Systems, Computerized; Middle Aged; Mortality; Myocardial Infarction; Neoplasms; Pravastatin; Prospective Studies; Risk Factors; Scotland | 1995 |
Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study.
Topics: Aged; Anticholesteremic Agents; Cerebral Infarction; Coronary Disease; Follow-Up Studies; Humans; Hypercholesterolemia; Japan; Lipids; Male; Middle Aged; Neoplasms; Patient Compliance; Pravastatin; Risk Factors | 2000 |
16 other study(ies) available for pravastatin and Neoplasms
| Article | Year |
|---|---|
D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study.
Topics: Adult; Aged; Biomarkers; Coronary Disease; Female; Fibrin Fibrinogen Degradation Products; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplasms; Pravastatin; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation; Venous Thromboembolism | 2018 |
Statins cause profound effects on gene expression in human cancer cells in vitro: the role of membrane microdomains.
Topics: Cell Line, Tumor; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Membrane Microdomains; Neoplasms; Pravastatin | 2012 |
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.
Topics: Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus; Follow-Up Studies; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mortality; Neoplasms; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Scotland; Survival Analysis | 2016 |
Re: The association between statins and cancer incidence in a veterans population.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Bias; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lung Neoplasms; Male; Neoplasms; Pravastatin; Prostatic Neoplasms; Simvastatin; United States; Veterans | 2008 |
Commentary on pravastatin and cancer: need for individual patient data meta-analyses.
Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; Humans; Japan; Meta-Analysis as Topic; Middle Aged; Neoplasms; Pravastatin; Reference Standards | 2010 |
Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
Topics: Angiogenic Proteins; Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Genes, MHC Class I; Humans; Inflammation; Lipid Metabolism; Liposomes; Male; Mice; Mice, Inbred C57BL; Neoplasms; Pravastatin | 2010 |
Efficacy and safety of more intensive lowering of LDL cholesterol.
Topics: Age Factors; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Meta-Analysis as Topic; Neoplasms; Odds Ratio; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2011 |
Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.
Topics: Cell Division; Cell Line, Tumor; Chromatography, High Pressure Liquid; Fluorescent Antibody Technique; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microscopy, Fluorescence; Neoplasms; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Tandem Mass Spectrometry | 2011 |
The PROSPER trial.
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Disease; Humans; Incidence; Killer Cells, Natural; Neoplasms; Patient Selection; Pravastatin | 2003 |
The PROSPER trial.
Topics: Aged; Anticholesteremic Agents; Humans; Hypercholesterolemia; Incidence; Neoplasms; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Research Design | 2003 |
The PROSPER trial.
Topics: Age Factors; Aged; Aging; Anticholesteremic Agents; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasms; Neovascularization, Pathologic; Pravastatin; Predictive Value of Tests; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study.
Topics: Adult; Aged; Anticholesteremic Agents; Australia; Cardiovascular Diseases; Causality; Cohort Studies; Humans; Middle Aged; Mortality; Neoplasms; New Zealand; Pravastatin; Randomized Controlled Trials as Topic; Registries; Reproducibility of Results; Time | 2003 |
Pravastatin and cancer: an unproven association.
Topics: Age Factors; Aged; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Neoplasms; Pravastatin; Risk Factors | 2007 |
Statins and cancer.
Topics: Case-Control Studies; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Odds Ratio; Pravastatin; Risk | 2007 |
The association between statins and cancer incidence in a veterans population.
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pravastatin; Proportional Hazards Models; Research Design; Retrospective Studies; Simvastatin; United States; Veterans | 2008 |
Effects of pravastatin in the elderly.
Topics: Aged; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Neoplasms; Pravastatin; Risk Factors; Time Factors | 2002 |